WEN-JEN HWU to Chemotherapy, Adjuvant
This is a "connection" page, showing publications WEN-JEN HWU has written about Chemotherapy, Adjuvant.
Connection Strength
0.188
-
The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017 Aug; 16(8):933-940.
Score: 0.085
-
Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg. 1996 Sep; 37(3):286-92.
Score: 0.040
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.022
-
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99.
Score: 0.015
-
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar; 67(3):657-66.
Score: 0.013
-
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
Score: 0.012